The ARBs have very comparable scientific profiles. They do, however, have different pharmacokinetic profiles, which can lead to some differences in efficacy. The newer products irbesartan, candesartan, telmisartan, and olmesartan have longer half-lives and duration of action than the older products losartan and valsartan. Twenty-four-hour blood pressure control could possibly be more readily achievable with the newer agents. Losartan and valsartan may need to be administered twice every day in sufferers needing better antihypertensive effects, whereas the agents with longer durations of action have no additional advantage when administered more than once daily. Of course, single dose product is at all times preferred.
Several double-blind, head-to-head comparative trials have evaluated the relative antihypertensive efficacy of the ARBs in sufferers with mild to moderate hypertension. The result is that the longer-appearing products may be more effective than losartan and valsartan at offering 24-hour blood pressure control. However a metaanalysis of 43 trials comparing the antihypertensive effects of ARBs found comparable antihypertensive efficacies inside the ARB class. Whether or not reported differences in efficacy are clinically related regarding morbidity and mortality has not been determined.

There are currently seven drugs on the market that are angiotensin II inhibitors. The table below shows characteristics of each of them and may be helpful for your MD in selecting the best one for your situation

Your Comments

Click here to add a comment

Name:


Location:


Email:


Comment:




Please enter the Captcha code:

There are no comments to display